Spirit-of-post,re 2017,10K "is-meaningless" Sleds love

New Post Public Reply Private Reply Replies (4) Message Board
CyberJ 4sleddogs #19646
725
Spirit-of-post,re 2017,10K "is-meaningless"

Sleds love ya! Love your enthusiasm, passion for SFOR and posts.

However, new and existing investors can do what they want. They can invest based on past , that's safe, and they can find that type of DD on here and it's harped on at ihub on everyday.

Last years revs IMO will be "unremarkable".IMO The big deals were not finalized. Numbers might reflect that .IMO Hope I am wrong. However It doesn't concern me , I understand what happened. Therefore its "meaningless to me". To me, not saying to everyone else.

If they will be very meaningful to you , I respect that. However to me SFOR is moving so fast now. What happened last year will be irrelevant , to me, other than the sales efforts , set the foundation for this year. Not sexy, will not drive the PPS. But those efforts, have made this years prospects breath taking.

The first quarter of this year? well if March see some significant payments it will be good, not sure what revenues they have received to date. I hope I am surprised. However a few huge payments can make the 1st quarter look spectacular.

Either way I fully expect SFOR to have good to amazing to spectacular revenues March , April though the rest of the year. I think we will see 10 mil to 20 mil in monthly revenues sooner than later look out for PCI and cell phone deals here and McAfee.

DOU with the help of venture capital money behind it, was able to attained record sales, adding tens of millions of monthly revenues.

If they can do it, then I believe ACS/McAfee/SFOR with backing from Ropes&Grey/TPG/Intel/IBM can do it , even more so!

That projection/forecast keeps me very bullish on SFOR. I have a very positive, forward looking expectation based on current news releases, and we have seen so many industry and government compliance mandates reaching compliance by using SFORs products, MFOOBA/push /Encryption are now the flavor of the month globally in the cyber security industry. The US government is now going to go all out to protect the government infrastructure , elections you post about that and know more about that then most posters here including me.

DOU and others are attaining unbelievable sales figures by stealing and using these same SFORs products.

ACS/McAfee are now doing the same,with bigger sales figures IMO as McAfee can add these products to existing customers as well as new clients resulting in amazing revenue streams, however this time SFOR will get their cut. It will be significant. This is what I am focused on. This is more significant than last years struggles.

On the Hangout we focus on DD on current and immediate and immediate future developments, patents, deals , compliance. Additionally we have been given by Mark Kay to assure us, a 90 day time line of HUGE revs that will lead to significant PRs that will lead to big spikes in PPS. How can than not supersede last year.

The 10K will have some explanation of outlooks developments that I am looking forward to reading so that is enlightening. The rev numbers wont effect my buying or selling. I am holding my shares very tightly knowing whats coming.

Sleds , for me, the immediate future of PRs, law suits developments , new deals, is what I am focused on, its the game changer for SFOR and longs. IMO It's more significant , and my friend if the term "meaningless" gives you a little indigestion, lol re the 2017 10K then I will substitute it with term "less significant" for me. :-)

Potential investors and current investors need to do what is comfortable for them. I am not a pumper. All my friends and family and even people I happened to meet I turn on to SFOR because it has been such a blessing to me and I want them to enjoy the blessing for their family's , or to get out of debt, pay off a student loan have money for retirement.

Me and my circle most of whom already own significant shares, are loading up and will be loading up based on what we know to be coming, not on the 10K which we don't have highest of expectations for because we already know the big deals and subsequent payments were delayed. Although I do hope to be surprised with some unexpectedly good revenues.

Very soon we will come upon a day that will be a life changing PR of significant revs for SFOR and Longs, and we will not look back from that day. IMO

The others can buy within their comfort zone, after the big revenue PRs hit. I look forward to that day, as that morning I will be drinkingmy french press coffee and in the after noon eating pop corn watching the PPS soar as so many will be trying to get a position, frantically trying to buy shares, realizing they need to price their buys well before the ask price to execute the trades, quickly driving the PPs , this happening all day, and going on for several days. Because of the size of the revenues coming are millions of monthly revenues, I see a huge gap up coming.

I can see a run from .10 to .15 coming very soon. We will see! We could go into .50 cents to $1.00 territory by the end of the year if patent dismissal is quickly reversed and Secure Auth settles and all current law suits settle and new round of 15 to 20 law suits announced. that would be in excess of 10 to 20 mil of monthly revenues. 100,000,000 + mil in damages.
It's happening!

Sorry for rambling!
Best wishes Sleds & fellow longs
&Blessings!


Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 5

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Flavors of Portugal at the 2025 Port Wine Fest

Updated Category News Views 380

Port Wine Fest: A Celebration of Portuguese Culture The Port Wine Fest is an exciting festival dedicated to showcasing Portuguese wines and cuisine. In 2025, it will embark on its third edition with events scheduled across various vibrant cities, including San Francisco, Chicago, and New York City, creating an unforgettable experience that combines culture, food, and fine...

Continue Reading
Earnings Projections for 5E Advanced Materials to Watch

Updated Category News Views 118

Understanding 5E Advanced Materials’ Earnings Expectations 5E Advanced Materials (NASDAQ: FEAM) is gearing up to unveil its quarterly earnings report soon. Investors are keenly awaiting the details, as quarterly performance can significantly influence stock trends and market sentiment. Projected Earnings per Share Analysts are estimating an earnings per share (EPS) of...

Continue Reading
Verano Launches Adult Cannabis Sales in Connecticut's Waterbury

Updated Category News Views 111

Verano Launches Adult Use Cannabis Sales at Zen Leaf Waterbury Zen Leaf Waterbury has achieved a significant milestone by transitioning its dispensary from medical-only sales to hybrid sales, allowing for adult use cannabis sales in Connecticut. Location and Accessibility of Zen Leaf Waterbury Conveniently located at 237 East Aurora Street in Waterbury, the fifth largest...

Continue Reading
Innovative Medical Education Suite Introduced by Treatment.com AI

Updated Category News Views 176

Revolutionizing Medical Education with AI Integration Treatment.com AI Inc. is making strides in medical education by unveiling a cutting-edge platform designed to enhance clinical skills training. This innovation aims to provide a more immersive and effective educational experience for medical students. The newly launched Medical Education Suite (MES) represents a...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 24

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading